Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Summary

JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).

Timeline

Start

2020-03-10

Primary completion

2023-01-03

Completion

2023-01-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to discontinue providing study drug to patients who have been on study treatment for more than two years”

Drugs

Indications